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ABSTRACT
Public health departments have limited evidence to understand and analyze the costs and benefits of different
health programs, including tuberculosis control and prevention programs. The study by Miller et. al addresses
this challenge to estimate costs and benefits of tuberculosis prevention programs in Texas and identify cost-
effective diagnostic and treatment combinations, thereby improving the evidence-based decision making
power of the public health departments.
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conomic evaluation of a public health program or intervention analyzes the costs and 
epidemiological effectiveness of alternate programs. The estimated incremental cost-
effectiveness ratio assists the decision makers, both practitioners and policy makers, with an 
objective metric to prioritize programs that are more cost-effective. In 2012, there were 9,945 
tuberculosis (TB) cases reported at the rate of 3.2 cases per 100,000 persons in United States; both 
cases reported and case rate had declined by 5.4% and 6.1% respectively compared to 20111. With 
declining TB incidence, public health departments may opt to divert resources allocated to TB 
control and prevention programs towards alternative health programs focused on other diseases. But 
this risks the reemergence of the TB epidemic with a potential to cause a higher disease burden that 
outweighs the health benefits derived by alternative programs.  
 
Using California demographic estimates, Porco et al conducted economic analysis of tuberculosis 
follow-up and evaluation interventions among new immigrants to United States and inferred that 
domestic follow-up and latent tuberculosis treatment of asymptomatic patients with abnormal chest 
radiograph was highly cost-effective2. Shepardson et al evaluated the cost-effectiveness of the 3HP 
program (12-dose regimen of weekly rifapentine plus isoniazid as directly observed treatment) 
compared to the 9H program (9 months of daily self-administered isoniazid), and inferred that 3HP 
is a cost-effective alternative to 9H3. Dowdy et al highlighted the challenges in economic analysis of 
diagnostic tests for tuberculosis, and cautioned against misleading results in analyzing the scale-up of 
TB diagnostics4.  Oxlade et al analyzed methodological differences in economic analysis of using 
assays for the detection of latent tuberculosis infection, and raised quality concerns of inconsistent 
results that necessitate the need  for specific and standardized guidelines in modeling approaches, 
inputs, assumptions, and presentation and interpretation of results5.  
 
In the article by Miller et. al, the authors analyze the value of TB prevention programs in Texas and 
analyze the cost-effectiveness of alternate diagnostic and treatment combinations. The academic 
public health department partnership of this study and the context sensitive analysis to the 
demographics of Texas strengthens the validity and translation of the findings into the decision 
making process of the public health departments. The estimated incremental cost-effectiveness 
ratios for the different tuberculosis diagnostic and treatment combinations provide not only 
objective metrics to prioritize among these combinations, but also compare against the costs and 
effectiveness of programs focused on other diseases. This study adds to the evidence-based policy 
making process of the health departments, and estimates the incremental cost-effectiveness ratios to 
objectively quantify the value of different TB control and prevention programs in Texas, and 
identify the optimal diagnostic and treatment combinations. 
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